Skip to main content

Table 1 Patients’ characteristics and clinical outcome

From: Perhexiline maleate in the treatment of fibrodysplasia ossificans progressiva: an open-labeled clinical trial

Case Age (years) Gender Dose of Pex Adverse events Acute inflammatory reaction (site)
1 36 Male 150 mg/d None None
2 26 Male 200 mg/d None M-7 m (right proximal thigh)
3 18 Female 75 mg/d None M-8 m (left hip), D-2 m (right jaw)
4 18 Female 14 mg/d None None
5 19 Male 100 mg/d None None
  1. Pex = Perhexiline maleate; M-7 m = Medication phase at 7 months.
  2. M-8 m = Medication phase at 8 months; D-2 m = Discontinuation phase at 2 months.